YAKUGAKU ZASSHI

Featured article

Volume 139 (2019) Issue 4 Pages 629-633

Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy

Tatsuo Kataoka, Hiroshi Sakurashita, Takanori Taogoshi, Ryo Nishigakiuchi, Tetsuya Murase, Satoru Izumitani, Yasuyuki Saeki, Hiroaki Matsuo

The combination of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin with rituximab (DA-EPOCH-R) is used for non-Hodgkin lymphoma patients. Febrile neutropenia (FN) is a common complication of treatment with myelo-suppressive chemotherapy, so preventing FN is important for maintaining chemotherapy dosage. Recently, pegfilgrastim has been used as the primary prophylaxis of FN in Japan, but there have been few cases reported using pegfilgrastim for the primary prophylaxis in DA-EPOCH-R. In this study, we retrospectively compared the efficacy of pegfilgrastim with that of filgrastim in patients receiving DA-EPOCH-R in Hiroshima University Hospital. Efficacy assessment was based on incidence of FN and serious neutropenia (neutrophil count <500/μL), hospitalization days and chemotherapy dosage level. Ten patients met the inclusion criteria: pegfilgrastim (n=5, 30 cycles) or filgrastim (n=5, 16 cycles). No difference in efficacy existed between pegfilgrastim and filgrastim in the first cycle; however, 2 of 5 patients in filgrastim group reduced dose level in the total cycles of chemotherapy, no patients in pegfilgrastim group reduced. In conclusion, pegfilgrastim seemed better than filgrastim for the primary prophylaxis in DA-EPOCH-R.

Editor’s picks

The combination of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin with rituximab (DA-EPOCH-R) is used for treatment of non-Hodgkin lymphoma. Febrile neutropenia (FN) is a common complication of treatment with myelo-suppressive chemotherapy, therefore, preventing FN is important for successful treatment. The authors compared the efficacy of pegfilgrastim with that of filgrastim in patients receiving DA-EPOCH-R and showed that pegfilgrastim seems to be better than filgrastim for the primary prophylaxis, maintaining chemotherapy dosage, and reducing hospital duration.

View the past featured articles

2019 Volume 139 Issue 4

Prediction of Wettability and Adhesion of Lotion to Skin Based on the OWRK Method Kaname Hashizaki, Kohei Sunaga, Yusuke Oda, Mai Bashuda, Miko Imai, Yukihiro Goto, Hiroyuki Taguchi, Yoshihiro Saito, Makiko Fujii
Adefovir Dipivoxil-induced Fanconi's Syndrome and Osteomalacia Following Multiple Bone Fractures in a Patient with Chronic Hepatitis B Takashi Makita, Hirotaka Kanzaki, Hideki Onishi, Ailee Ikeda, Akinobu Takaki, Nozomu Wada, Yasuto Takeuchi, Tetsuya Yasunaka, Fusao Ikeda, Hidenori Shiraha, Yuta Tanaka, Shigeki Nishihara, Kiminaka Murakawa, Yoshihisa Kitamura, Hiroyuki Okada, Toshiaki Sendo
Effectiveness of Steroid Rotation in a Japanese Patient with Hiccups Caused by Dexamethasone: a Case Report Hiroki Hosokawa, Hideaki Shimoda, Takayuki Ishii

View all articles in Current issue

Register with J-STAGE for free!